Abstract:You have accessJournal of UrologyCME1 May 2022MP06-09 SINGLE CELL ANALYSES OF MURINE UROTHELIAL CARCINOMA CELLS REVEAL A ROLE OF TUMOR-ASSOCIATED MACROPHAGES IN RESPONSE TO ANTI-PD1 THERAPY Dongbo Xu, Li Wang, Yali Zhang, Yanqing Wang, Xiaojing Zhang, Yue Wu, Gary Smith, Bo Xu, Prashant Singh, Yuesheng Zhang, David Goodrich, Jianmin Wang, and Qiang Li Dongbo XuDongbo Xu More articles by this author , Li WangLi Wang More articles by this author , Yali ZhangYali Zhang More articles by this author , Yanqing WangYanqing Wang More articles by this author , Xiaojing ZhangXiaojing Zhang More articles by this author , Yue WuYue Wu More articles by this author , Gary SmithGary Smith More articles by this author , Bo XuBo Xu More articles by this author , Prashant SinghPrashant Singh More articles by this author , Yuesheng ZhangYuesheng Zhang More articles by this author , David GoodrichDavid Goodrich More articles by this author , Jianmin WangJianmin Wang More articles by this author , and Qiang LiQiang Li More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002523.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Approximately 80% of patients with advanced bladder cancer do not respond to immune checkpoint inhibitor (ICI) immunotherapy. The molecular mechanism of ICI treatment response remains unknown largely due to the lack of clinically relevant immunocompetent mouse models. METHODS: We developed a syngeneic triple knockout (TKO: Trp53/Pten/Rb1) bladder cancer model in immunocompetent C57 BL/6J mice. Mouse urothelial cells (Trp53f/f, Ptenf/f, Rb1f/f) were transfected ex vivo with Ad5CMVCre (Adenovirus Cre recombinase driven by a CMV promoter). The TKO urothelial cells were subcutaneously injected into immunocompetent C57 BL/6J for tumor formation. The tumors were treated with an anti-PD1 antibody (BioXcell, RMP1-14, 200 μg, intraperitoneally twice weekly) (n=9) or a control IgG (n=9). Single cell analyses were performed for tumor xenografts from control IgG (n=2), responders (30% less than the median of control tumors) (n=2) and non-responders (n=2) using PTPRC (also named CD45) expression as an immune cell marker. Seurat package was used for data analysis including dimension reduction, cell clustering, and identification of cell markers. SingleR package was utilized to identify the cell types. Immunohistochemistry (IHC) of CD8 and F4/80 was performed to identify T cells and macrophages respectively. RESULTS: Anti-PD-1 immunotherapy resulted in a mixed pattern of treatment responses in individual tumors. Eight clusters of immune cells were identified (basophils, B cells, dendritic cells, macrophages, monocytes, neutrophils, NK cell, and T cells) in ICI treated xenografts. Responder xenografts displayed significantly increased immune cell infiltration (15.2%, 742 immune cells/4861 total cells) compared to the non-responder tumors (10.1%, 452 immune cells/4459 total cells, Fisher Exact Test p<0.0001). Specifically, there were more T cells (46/4861 vs 18/4459, p=0.002), and macrophages (420/4861 vs 287/4459, p=0.002) in responder xenografts than in non-responder xenografts. Compared to control IgG tumors, a near complete response tumor exhibited an immune-inflamed phenotype with significant infiltration of T cells and macrophages, whereas non-responder tumors showed no significant change of T cells and macrophages infiltration. CONCLUSIONS: The higher percentage of T cells and macrophages tumor infiltration in responders suggests a potential role of innate immune microenvironment for the ICI treatment response. Modulating tumor associated macrophage may overcome the resistance to ICI immunotherapy. Source of Funding: This research work was supported in part by NIH Grants, K08CA252161(Li, Q), P30CA016056 (NCI Cancer Center Core Support Grant), the Roswell Park Alliance Foundation and the Friends of Urology Foundation © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e80 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Dongbo Xu More articles by this author Li Wang More articles by this author Yali Zhang More articles by this author Yanqing Wang More articles by this author Xiaojing Zhang More articles by this author Yue Wu More articles by this author Gary Smith More articles by this author Bo Xu More articles by this author Prashant Singh More articles by this author Yuesheng Zhang More articles by this author David Goodrich More articles by this author Jianmin Wang More articles by this author Qiang Li More articles by this author Expand All Advertisement PDF DownloadLoading ...

423: Tumor Exosomes Expressing FAS Ligand Mediate CD8+ T Cell Apoptosis

c-FOS promotes trail-induced apoptosis by repressing c-FLIP(L)

Abstract LB-341: CD95/FAS promotes tumorigenesis

1341: Targeted Therapeutic Ablation of the Prostate Epithelium Using Adenoviral Mediated Delivery of ICASPASES9 Induce Apoptosis at Both Epithelium and Stroma in MT-PRL Mice

Association of CD8 T cell apoptosis and <i>EGFR</i> mutation in non-small lung cancer patients

BCG induced gene transactivation inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic agents

Activated T cell exosomes promote tumor invasion via Fas signaling pathway.

Apoptosis of Tumor-Infiltrating T Lymphocytes: a New Immune Checkpoint Mechanism

1352: Estradiol Enhances Expression of Smooth Muscle Cellspecific Markers in Prostatic Stromal Cells Through Paracrine Stimulation of Transforming Growth Factor Beta from Prostatic Epithelial Cell Line BPH-1

MP98-14 CATHEPSIN S INHIBITION CHANGES REGULATORY T-CELL ACTIVITY IN REGULATING BLADDER CANCER AND IMMUNE CELL PROLIFERATION AND APOPTOSIS

[Apoptosis and expression of Fas/FasL in tumor infiltrating dendritic cells in human endometrioid adenocarcinoma].

Depleting Intratumoral Cd4(+)Cd25(+) Regulatory T Cells Via Fasl Protein Transfer Enhances The Therapeutic Efficacy Of Adoptive T Cell Transfer

[Expression of Fas Ligand on Peritumoral Lymphocytes and Its Association with Apoptosis of Colorectal Carcinomas].

Study on the Regulation of PKCα on Apoptosis Inhibited by FGF‐2 in Small Cell Lung Cancer

680 ADOPTIVE TRANSFER OF PSMA-SPECIFIC, TGF-β INSENSITIVE MEMORY CD8+ T CELLS: SUPPRESSION OF HUMAN PROSTATE CANCER (CAP)

757: Cytokines, Vitamins, and Small Molecules Modulate the Direct Antitumor Effect of BCG and Alter P21 Transactivation

Expression of Concern: Lymph Node Mapping in Patients with Penile Cancer Undergoing Pelvic Lymph Node Dissection

Functional investigation of Fas ligand expressions in human non-small cell lung cancer cells and its clinical implications.

MP06-09 SINGLE CELL ANALYSES OF MURINE UROTHELIAL CARCINOMA CELLS REVEAL A ROLE OF TUMOR-ASSOCIATED MACROPHAGES IN RESPONSE TO ANTI-PD1 THERAPY

Activated Cytotoxic Lymphocytes Promote Tumor Progression by Increasing the Ability of 3LL Tumor Cells to Mediate MDSC Chemoattraction Via Fas Signaling.

Fas Ligand Expression in Colon Cancer: A Possible Mechanism of Tumor Immune Privilege